Расширенный поиск

О безопасности длительнодействующих β2-агонистов. Взгляд кардиолога

Полный текст:

Об авторе

И. С. Явелов
ГКБ № 29
г. Москва

Список литературы

1. The task force on beta-blockers of the European Society of Cardiology. Expert consensus document on β-adrenergic receptor blockers. Eur. Heart J. 2004; 25: 1341–1362.

2. Haverkamp W., Breithardt G., Cammm A.J. et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Eur. Heart J. 2000; doi:10.1053/euhj.2000.2249.

3. Roden D.M. Drug-Induced Prolongation of the QT Interval. N. Engl. J. Med. 2004; 350: 1013–1022.

4. Salpeter S.R., Ormiston T., Salpeter E.E. Meta-analysis cardiovascular effects of β-agonists in patients with asthma and COPD. Chest 2004; 125: 2309–2321.

5. Burgess C., Ayson M., Rajasingham S. et al. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. Eur J. Clin. Pharmacol. 1998; 54: 141–147.

6. Cazzola M., Imperatore F., Salzillo A. et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114; 411-415.

7. Campbell S.C., Criner G.J., Levine B.E. et al. Cardiac safety of formoterol 12 mg twice daily in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2006; doi:10.1016/j.pupt.2006.06.003.

8. Cazzola M., Matera M.G., Donner C.F. Inhaled β2 -adrenoceptor agonists cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65: 1595–1610.

9. Lemaitre R.N., Siscovick D.S., Psaty B.M. et al. Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest. Am. J. Med. 2002; 113: 711–716.

10. Au D.H., Lemaitre R.N., Randall J. et al. The risk of myocardial infarction associated withInhaled β-adrenoceptor agonists. Am. J. Respir. Crit. Care Med. 2000; 161: 827–830.

11. Au D.H., Curtis J.R., Every N.R. et al. Association between inhaled β-agonists and the risk of unstable angina and myocardial infarction. Chest 2002; 121: 846–851.

12. Suissa S., Assimes T., Ernst P. Risk of acute myocardial infarction Inhaled short acting β-agonist use in COPD and the risk of acute myocardial infarction. Thorax 2003; 58: 43–46.

13. Coughlin S.S., Metayer C., McCarthy E.P. et al. Respiratory illness, β-agonists, and risk of idiopathic dilated cardiomy opathy: the Washington, DC, Dilated Cardiomyopathy Study. Am. J. Epidemiol. 1995; 142: 395–403.

14. Sengstock D.M., Obeidat O., Pasnoori V. et al. Asthma, β-agonists, and development of congestive heart failure: results of the ABCHF study. J. Card. Fail. 2002; 8: 232–238.

15. Au D.H., Udris E.M., Curtis J.R. Association between chronic heart failure and inhaled β2 -adrenoceptor agonists. Am. Heart J. 2004; 148: 915–920.

16. Nelson H.S., Weiss S.T., Bleecker E. R. et al. The Salmeterol multicenter asthma research trial. A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus Salmeterol. Chest 2006; 129: 15–26.

Для цитирования:

Явелов И.С. О безопасности длительнодействующих β2-агонистов. Взгляд кардиолога. Пульмонология. 2007;(1):112-116.

For citation:

Yavelov I.S. About safety of long-acting β2-agonists. A cardiologist's point of view. PULMONOLOGIYA. 2007;(1):112-116. (In Russ.)

Просмотров: 22

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)